{"id":"W3201850473","doi":"10.1016/j.annonc.2021.08.1098","title":"585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Abiraterone; Prostate cancer; Oncology; Abiraterone acetate; Internal medicine; Cancer; Gynecology; Androgen deprivation therapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001473072,0.0007800995,0.001128308,0.0003550341,0.000229384,0.0009964691,0.0005949124,0.000850278,0.01174698],"category_scores_gemma":[0.002280402,0.000328116,0.002139978,0.0004581397,0.0004946645,0.0005665743,0.0003982212,0.002441486,0.001693333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007271701,"about_ca_system_score_gemma":0.00125727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008005312,"about_ca_topic_score_gemma":0.001927644,"domain_scores_codex":[0.9993568,0.0003450331,0.00002474558,0.0001038976,0.00009827077,0.00007119705],"domain_scores_gemma":[0.9991814,0.0002728989,0.0002004821,0.0001022196,0.00007718644,0.0001657277],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7852049,0.00388477,0.007391009,0.001863118,0.00506254,0.0002907137,0.0001154846,0.003330386,0.0111355,0.001322577,0.02243763,0.1579614],"study_design_scores_gemma":[0.7919102,0.1367911,0.03110264,0.0003727949,0.005931477,0.000998339,0.0001234717,0.004951796,0.003293726,0.003021654,0.02143737,0.0000654644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9428329,0.00768727,0.002579204,0.002529538,0.0004733232,0.001852894,0.01440999,0.0005554912,0.02707944],"genre_scores_gemma":[0.9772723,0.002531338,0.001401628,0.002190765,0.0002988272,0.001087945,0.009288525,0.00009553786,0.005833149],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01174698,"threshold_uncertainty_score":0.03929752,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08722032634478372,"score_gpt":0.4196805134468253,"score_spread":0.3324601871020416,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}